The Association between Androgenic Hormone Levels and the Risk of Developing Coronary Artery Disease (CAD)
,
Abstract
Background: The aim of the study was to evaluate the relationship between the serum levels of androgens and Coronary Artery Disease (CAD) in an Iranian population.
Methods: Male individuals admitted to Tehran Heart Center and Sina Hospital, Tehran, Iran from 2011-2012 were categorized into CAD and control groups based on selective coronary angiography. Baseline demographic data, including age, BMI, diabetes, and a history of hypertension were recorded. Patients were also assessed for their serum levels of total testosterone, free testosterone, estradiol, dehydroepi and rosterone sulfate (DHEA-S), and Sex Hormone Binding Globulin (SHBG). Data analysis was carried out chi-square and ANOVA tests as well as logistic regression analysis.
Results: Two hundred patients were in the CAD group and 135 individuals in control group. In the CAD group, 69 had single-vessel disease, 49 had two-vessel diseases, and 82 had three-vessel diseases. Statistically significant differences were observed between the individuals in the two groups with respect to age (P<0.0001), diabetes (P<0.0001), and a history of hypertension (P=0.018). The serum levels of free testosterone (P=0.048) and DHEA-S (P<0.0001) were significantly higher in the control group than in the CAD group; however, the serum level of SHBG was higher in the CAD group than in the control group (P=0.007). Results of the logistic regression analysis indicated that only age (P=0.042) and diabetes (P=0.003) had significant relationships with CAD.
Conclusion: Although the serum levels of some of the androgens were significantly different between the two groups, no association was found between androgenic hormone levels and the risk of CAD, due mainly to the effect of age and diabetes.
Lippi G, Franchini M, Cervellin G (2013). Di-agno¬sis and management of ischemic heart disease. Semin Thromb Hemost, 39 (2): 202-13.
Richard A (2007). Coronary heart disease. In: Cecil es¬sen¬tial of medicine, Eds, Lange L. 7th edition. United States, pp 97-98.
Liu PY, Death AK, Handelsman DJ (2003). Andro¬gens and cardiovascular disease. Endocr Rev, 24(3): 313−340.
Channer KS, Jones TH (2003). Cardiovascular ef¬fects of testosterone: implications of the ‘male menopause’? Heart, 89(2): 121−122.
Malkin CJ, Pugh PJ, Jones TH, Channer K (2003). Testosterone for secondary pre-vention in men with ischaemic heart dis-ease? Q J Med, 96(7): 521−529.
Manson JE, Bassuk SS, Harman SM, Brinton EA, Ce¬dars MI, Lobo R, et al (2006). Postmenopau¬sal hormone therapy: new ques¬tions and the case for new clinical tri-als. Meno¬pause, 13(1): 139−147.
Rohrmann S, Platz EA, Selvin E, Shiels MS, Joshu CE, Menke A, et al (2011).The prevalence of low sex steroid hormone concentrations in men in the Third Na-tional Health and Nutri¬tion Ex¬amination Survey (NHANES III). Clin Endo¬crinol, 75(2):232-9.
Ohlsson C, Labrie F, Barrett-Connor E, Karlsson MK, Ljunggren O, Vandenput L, et al (2010). Low serum levels of dehy-droepiandrosterone sul¬fate predict all-cause and cardiovascular mor¬tal¬ity in elder-ly Swedish men. J Clin Endo¬crinol Metabol, 95(9):4406-14.
Webb CM, Elkington AG, Kraidly MM, Kee-nan N, Pennell DJ, Collins P (2008). Ef-fects of oral tes¬tosterone treatment on myocardial perfu¬sion and vascular func-tion in men with low plasma testosterone and coronary heart dis¬ease. Am J Cardiol, 101(5):618-24.
Kravchenko AI, Provotorov VM (2008). Age-re¬lated androgen deficiency in men with is¬chemic heart disease. Adv Gerontol, 21(2):311-3.
Hyde Z, Norman PE, Flicker L, Hankey GJ, Al¬meida OP,McCaul KA, et al (2012). Low free testosterone predicts mortality from cardiovas¬cu¬lar disease but not other caus-es: the Health in Men Study. J Clin Endo-crinol Metabol, 97(1):179-89
Davoodi G, Amirezadegan A, Borumand MA, Dehkori MR, Kazemisaeid A, Yamin-isharif A (2007).The relationship between level of andro¬genic hormones and coro-nary artery dis¬ease in men. Cardiovasc J Afr,18(6):362-6.
Yarnell JW, Beswick AD, Sweetnam PM, Ri-ad-Fahmy D (1993). Endogenous sex hormones and ischemic heart disease in men. Arterioscler Thromb, 13(4):517-20.
Webb CM, Collins P (2010). Testosterone and cor¬o¬nary artery disease in men. Ma-turitas, 67(1): p. 15-19.
Nam UH, Wang M, Crisostomo PR, Markel TA, Lahm T, Meldrum KK, et al (2007). The effect of chronic exogenous andro-gen on myocardial function following acute ischemia-reperfusion in hosts with different baseline levels of sex ster¬oids. J Surg Res, 142(1):113-8.
Shores MM, Smith NL, Forsberg CW, Ana-walt BD, Matsumoto AM (2012).Testosterone treat¬ment and mortali-ty in men with low testos¬terone levels. J Clin Endocrinol Metabol, 97(6):2050-8
Allan CA, Robert I, McLachlan (2004). Age-re¬lated changes in testosterone and the role of re¬place¬ment therapy in older men. Clin Endo¬crinol, 60(6): 653−670.
Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al (2010). Adverse events associated with testos-terone administra¬tion. N Engl J Med, 363(2):109-22.
Gensini GG (1983). A more meaningful scoring sys¬tem for determining theseverity of coronary heart disease. Am J Cardiol, 51(3): 606.
Ravaglia G, Forti P, Maioli F, Sacchetti L, Na-tivio V, Scali CR, et al (2002). Dehydroepi-andros¬terone-sulfate serum levels and common age-re¬lated diseases: results from a cross-sectional Ital¬ian study of a general elderly population. Exp Gerontol, 37(5): 701−712.
Rhoden EL, Ribeiro EP, Teloken C, Souto CA (2005). Diabetes mellitus is associated with sub¬normal serum levels of free tes-tosterone in men. BJU Int, 96(6): 867−870.
Dhindsa S, Prabhakar S, Sethi M, Bandyo-padhyay A, Chaudhuri A, Dandona P (2004). Frequent oc¬currence of hy-pogonadotropichypogonadis¬min type 2 diabetes, J Clin Endocrinol Metab, 89(11):5462-8.
Dandona P, Dhindsa S (2011). Update: Hy-pogonad¬otropichypogonadism in type 2 diabe¬tes and obesity. J Clin Endocrinol Metabol, 96(9):2643-51.
Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C (1999). Natural androgens in¬hibit male atherosclerosis: a study in cas¬trated, cholesterol-fed rabbits. Circ Res, 84(7): 813−819.
Corcoran MP, Meydani M, Lichtenstein AH, Schaefer EJ, Dillard A, Lamon-Fava S (2010). Sex hormone modulation of pro-inflammatory cytokine and C-reactive pro-tein expression in mac¬rophages from old-er men and postmeno¬pau¬sal women. J Endocrinol, 206(2):217-24.
Jian Cao, Bing-po Zhu, Hao Wang, Jian Li, Yu Ding,Xiao-ying Li (2010). Sex Hor-mones and An¬drogen Receptor: Risk Fac-tors of Coronary Heart Disease in Elderly Men. Chin Med Sci J, 25(1): pp. 44-49.
Li L, Guo CY, Jia EZ, Zhu TB, Wang LS, Cao KJ, et al (2012). Testosterone is nega-tively associ¬ated with the severity of coro-nary athero¬sclero¬sis in men. Asian J Androl, 14(6):875-8.
English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS (2000). Men with coro¬nary artery disease have lower levels of andro¬gens than men with normal coronary angio¬grams. Eur Heart J, 21(11): 890−894.
Sieminska L, Wojciechowska C, Swietochow-ska E, Marek B, Kos-Kudla B, Kajdaniuk D, et al (2003). Serum free testosterone in men with coro¬nary artery atherosclerosis. Med Sci Monit, 9(5): CR162−CR166.
Yildirir A, Kabakci G, Can I, Erbas B (2001). Men with coronary artery disease have lower lev¬els of androgens than men with normal coro¬nary an¬giograms. Eur Heart J, 22(7): 612−613.
| Files | ||
| Issue | Vol 45 No 1 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Coronary Artery Disease (CAD) Androgenic hormones Testosterone DHEA-S Estradiol SHBG | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
